Differential proteomic profiling of primary and recurrent chordomas

Chen,Su; Xu,Wei; Jiao,Jian; Jiang,Dongjie; Liu,Jian; Chen,Tenghui; Wan,Zongmiao; Xu,Leqin; Zhou,Zhenhua; Xiao,Jianru

doi:10.3892/or.2015.3818

Differential proteomic profiling of primary and recurrent chordomas

Authors:
- Su Chen
- Wei Xu
- Jian Jiao
- Dongjie Jiang
- Jian Liu
- Tenghui Chen
- Zongmiao Wan
- Leqin Xu
- Zhenhua Zhou
- Jianru Xiao
View Affiliations

Affiliations: Department of Bone Tumor Surgery, Changzheng Hospital, Second Military Medical University, Shanghai 200003, P.R. China, Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA, Department of Bioinformatics and Computational Biology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
Published online on: February 26, 2015 https://doi.org/10.3892/or.2015.3818
Pages: 2207-2218

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chordomas are locally destructive tumors with high rates of recurrence and a poor prognosis. The mechanisms involved in chordoma recurrence remain largely unknown. In the present study, we examined the proteomic profile of a chordoma primary tumor (CSO) and a recurrent tumor (CSR) through mass spectrum in a chordoma patient who underwent surgery. Bioinformatic analysis of the profile showed that 359 proteins had a significant expression difference and 21 pathways had a striking alteration between the CSO and the CSR. The CSR showed a significant increase in carbohydrate metabolism. Immunohistochemistry (IHC) confirmed that the cancer stem cell marker activated leukocyte cell adhesion molecule (ALCAM or CD166) expression level was higher in the recurrent than that in the primary tumor. The present study analyzed the proteomic profile change between CSO and CSR and identified a new biomarker ALCAM in recurrent chordomas. This finding sheds light on unraveling the pathophysiology of chordoma recurrence and on exploring more effective prognostic biomarkers and targeted therapies against this devastating disease.

View Figures

View References

1	Stacchiotti S, Casali PG, Lo Vullo S, et al: Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers. Ann Surg Oncol. 17:211–219. 2010. View Article : Google Scholar
2	DeLaney TF, Liebsch NJ, Pedlow FX, et al: Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. Int J Radiat Oncol Biol Phys. 74:732–739. 2009. View Article : Google Scholar :
3	Zhou H, Chen CB, Lan J, et al: Differential proteomic profiling of chordomas and analysis of prognostic factors. J Surg Oncol. 102:720–727. 2010. View Article : Google Scholar : PubMed/NCBI
4	Wisniewski JR, Zougman A, Nagaraj N and Mann M: universal sample preparation method for proteome analysis. Nat Methods. 6:359–362. 2009. View Article : Google Scholar : PubMed/NCBI
5	Vogel C and Marcotte EM: Calculating absolute and relative protein abundance from mass spectrometry-based protein expression data. Nat Protoc. 3:1444–1451. 2008. View Article : Google Scholar : PubMed/NCBI
6	Lu P, Vogel C, Wang R, Yao X and Marcotte EM: Absolute protein expression profiling estimates the relative contributions of transcriptional and translational regulation. Nat Biotechnol. 25:117–124. 2007. View Article : Google Scholar
7	Benjamini Y and Hochberg Y: Controlling the false discovery rate - a practical and powerful approach to multiple testing. J R Stat Soc B. 57:289–300. 1995.
8	Conesa A, Gotz S, Garcia-Gomez JM, Terol J, Talon M and Robles M: Blast2GO: a universal tool for annotation, visualization and analysis in functional genomics research. Bioinformatics. 21:3674–3676. 2005. View Article : Google Scholar : PubMed/NCBI
9	Yamada T, Letunic I, Okuda S, Kanehisa M and Bork P: IPath2.0: interactive pathway explorer. Nucleic Acids Res. 39:W412–W415. 2011. View Article : Google Scholar : PubMed/NCBI
10	Shimizu-Hirota R, Sasamura H, Kuroda M, Kobayashi E and Saruta T: Functional characterization of podocan, a member of a new class in the small leucine-rich repeat protein family. FEBS Lett. 563:69–74. 2004. View Article : Google Scholar : PubMed/NCBI
11	Hoover KB, Liao SY and Bryant PJ: Loss of the tight junction MAGUK ZO-1 in breast cancer: relationship to glandular differentiation and loss of heterozygosity. Am J Pathol. 153:1767–1773. 1998. View Article : Google Scholar : PubMed/NCBI
12	Liu W, Liu B, Xin L, Zhang Y, Chen X, Zhu Z and Lin Y: Downregulated expression of complement factor I: a potential suppressive protein for gastric cancer identified by serum proteome analysis. Clin Chim Acta. 377:119–126. 2007. View Article : Google Scholar
13	Ohnuma SI: Cancer diagnosis and treatment. Google Patents. 2011
14	Ostrow KL, Park HL, Hoque MO, et al: Pharmacologic unmasking of epigenetically silenced genes in breast cancer. Clin Cancer Res. 15:1184–1191. 2009. View Article : Google Scholar : PubMed/NCBI
15	Tachezy M, Zander H and Wolters-Eisfeld G: Activated leukocyte cell adhesion molecule (CD166): an ‘inert’ cancer stem cell marker for non-small cell lung cancer? Stem Cells. 32:1429–1436. 2014. View Article : Google Scholar : PubMed/NCBI
16	Ibrahim SA, Reed KR, Clarke AR, Pritchard DM and Jenkins JR: Sa1992 SFRS2 and CDC5L interaction: an insight into downstream events following APC deletion during colorectal carcinogenesis. Gastroenterology. 144:S353–S354. 2013.
17	Palmieri D, Bouadis A, Ronchetti R, Merino MJ and Steeg PS: Rab11a differentially modulates epidermal growth factor-induced proliferation and motility in immortal breast cells. Breast Cancer Res Treat. 100:127–137. 2006. View Article : Google Scholar : PubMed/NCBI
18	Klement RJ and Kammerer U: Is there a role for carbohydrate restriction in the treatment and prevention of cancer? Nutr Metab. 8:752011. View Article : Google Scholar
19	Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfør K, Rofstad EK and Mueller-Klieser W: High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res. 60:916–921. 2000.PubMed/NCBI
20	Seyfried TN and Shelton LN: Cancer as a metabolic disease. Nutr Metab. 7:72010. View Article : Google Scholar
21	Skonier JE, Bowen MA, Emswiler J, Aruffo A and Bajorath J: Recognition of diverse proteins by members of the immunoglobulin superfamily: delineation of the receptor binding site in the human CD6 ligand ALCAM. Biochemistry. 35:12287–12291. 1996. View Article : Google Scholar : PubMed/NCBI
22	Weidle HU, Eggle D, Klostermann S and Swart GW: ALCAM/CD166: cancer-related issues. Cancer Genom Proteom. 7:231–243. 2010.
23	Van Kilsdonk JW, Wilting RH, Bergers M, van Muijen GN, Schalkwijk J, van Kempen LL and Swart GW: Attenuation of melanoma invasion by a secreted variant of activated leukocyte cell adhesion molecule. Cancer Res. 68:3671–3679. 2008. View Article : Google Scholar : PubMed/NCBI
24	Ofori-Acquah SF and King JA: Activated leukocyte cell adhesion molecule: a new paradox in cancer. Transl Res. 151:122–128. 2008. View Article : Google Scholar : PubMed/NCBI
25	Ihnen M, Müller V, Wirtz RM, et al: Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer. Breast Cancer Res Treat. 112:419–427. 2008. View Article : Google Scholar : PubMed/NCBI
26	Mezzanzanica D, Fabbi M, Bagnoli M, et al: Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients. Clin Cancer Res. 14:1726–1733. 2008. View Article : Google Scholar : PubMed/NCBI
27	Tachezy M, Zander H, Marx AH, Stahl PR, Gebauer F, Izbicki JR and Bockhornet M: ALCAM (CD166) expression and serum levels in pancreatic cancer. PLoS One. 7:e390182012. View Article : Google Scholar : PubMed/NCBI
28	Tachezy M, Effenberger K, Zander H, et al: ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients. Int J Cancer. 131:396–405. 2012. View Article : Google Scholar
29	Tachezy M, Zander H, Gebauer F, Marx A, Kaif JT, Izbicki JR and Bockhorn M: Activated leukocyte cell adhesion molecule (CD166) - its prognostic power for colorectal cancer patients. J Surg Res. 177:e15–e20. 2012. View Article : Google Scholar : PubMed/NCBI
30	Tachezy M, Zander H, Marx AH, et al: ALCAM (CD166) expression as novel prognostic biomarker for pancreatic neuroendocrine tumor patients. J Surg Res. 170:226–232. 2011. View Article : Google Scholar : PubMed/NCBI
31	Ishiguro F, Murakami H, Mizuno T, et al: Membranous expression of activated leukocyte cell adhesion molecule contributes to poor prognosis and malignant phenotypes of non-small-cell lung cancer. J Surg Res. 179:24–32. 2013. View Article : Google Scholar
32	Simon R, Mirlacher M and Sauter G: Immunohistochemical analysis of tissue microarrays. Methods Mol Biol. 664:113–126. 2010. View Article : Google Scholar : PubMed/NCBI